About johnson & johnson - JNJ
JNJ At a Glance
| Phone | 1-732-524-0400 | Revenue | 94.18B | |
| Industry | Pharmaceuticals: Major | Net Income | 26.80B | |
| Sector | Health Technology | 2025 Sales Growth | 6.034% | |
| Fiscal Year-end | 12 / 2026 | Employees | 140,800 | |
| View SEC Filings |
JNJ Valuation
| P/E Current | 21.535 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 18.819 |
| Price to Sales Ratio | 5.356 |
| Price to Book Ratio | 6.131 |
| Price to Cash Flow Ratio | 20.56 |
| Enterprise Value to EBITDA | 15.87 |
| Enterprise Value to Sales | 5.666 |
| Total Debt to Enterprise Value | 0.092 |
JNJ Efficiency
| Revenue/Employee | 668,877.841 |
| Income Per Employee | 190,369.318 |
| Receivables Turnover | 5.482 |
| Total Asset Turnover | 0.497 |
JNJ Liquidity
| Current Ratio | 1.028 |
| Quick Ratio | 0.765 |
| Cash Ratio | 0.371 |
JNJ Profitability
| Gross Margin | 68.621 |
| Operating Margin | 27.739 |
| Pretax Margin | 34.595 |
| Net Margin | 28.461 |
| Return on Assets | 14.133 |
| Return on Equity | 35.03 |
| Return on Total Capital | 20.48 |
| Return on Invested Capital | 23.749 |
JNJ Capital Structure
| Total Debt to Total Equity | 60.499 |
| Total Debt to Total Capital | 37.694 |
| Total Debt to Total Assets | 24.764 |
| Long-Term Debt to Equity | 50.081 |
| Long-Term Debt to Total Capital | 31.203 |
Johnson & Johnson in the News
Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility
Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over 500 manufacturing jobs plus 4,000 construction jobs.
Texas AG sues Kenvue, J&J over 'deceptively marketing' Tylenol to pregnant women
Texas Attorney General Ken Paxton is suing the makers of Tylenol over allegedly deceptively marketing the over-the-counter drug to pregnant women.
AstraZeneca to invest $50B in US economy by 2030
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence in the company's largest market.
Behind the scenes: Tech titans meet Trump, Apple's Cook praises pro-business policies
Apple's Tim Cook spoke by satellite and 20 other AI and tech executives joined the White House to discuss onshoring and building up American manufacturing.
J&J has enough support from claimants for $6.5 billion talc settlement: report
Johnson & Johnson is reportedly nearing enough support to finalize a $6.5 billion settlement for lawsuits related to cancer cases linked to its baby powder and other talc products.
Left-wing activism rampant in corporate shareholder proposal process: report
A Securities and Exchange Commission process for approving shareholder proposals favors a left-wing bent in corporate policies, claims a watchdog, citing audits from 2018-2022.
Pharma giant adds Israel to list of Middle East markets after omission raises questions
Johnson & Johnson has added Israel to its Customer Connect order management website after questions rose over why it was excluded while "Palestine" was not.
Johnson & Johnson proposes to pay $6.5B to settle talc ovarian cancer lawsuits in US
Through a bankruptcy filing of its subsidiary company, J&J will be able to resolve about 99.75% of the pending talc lawsuits against the company and its affiliates in the U.S.
Judge certifies Johnson & Johnson shareholder class action over talc disclosures
A federal judge said Johnson & Johnson shareholders may pursue as a class action their lawsuit accusing the company of concealing how its talc products were contaminated by asbestos.
Coalition calls on Congress to repeal Biden's prescription drug price controls
More than 40 groups have signed onto a letter asking Congress to end the prescription drug price control scheme included in the Inflation Reduction Act.